Non–Small Cell Lung Cancer Coverage from Every Angle

Stephanie T. Schmidt, PhD, on Neoadjuvant Chemotherapy and Immune-Based Treatments in NSCLC

Posted: Thursday, January 6, 2022

Stephanie T. Schmidt, PhD, of The University of Texas MD Anderson Cancer Center, discusses the concept of immunomics, how it is used to examine the effects of neoadjuvant chemotherapy and immune-based treatments in patients with non–small cell lung cancer, and the clinical implications of her findings for treatment selection or patient eligibility for a variety of therapies.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.